You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Boehringer Ingelheim
Colorcon
Harvard Business School

Last Updated: February 26, 2024

Lilly Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Lilly
International Patents:30
US Patents:1
Tradenames:85
Ingredients:81
NDAs:105

Drugs and US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly AMPICILLIN SODIUM ampicillin sodium INJECTABLE;INJECTION 062565-002 Apr 4, 1985 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 050477-005 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial
Lilly MANDOL cefamandole nafate INJECTABLE;INJECTION 050504-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Lilly NEOTRIZINE trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) SUSPENSION;ORAL 006317-012 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 RE39050 ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 5,658,590*PED ⤷  Try a Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-005 Dec 24, 2003 5,229,382*PED ⤷  Try a Trial
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 5,731,342 ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-002 Nov 26, 2002 5,658,590*PED ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 2008-08-04
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 2008-05-08
➤ Subscribe For Injection 1g/vial ➤ Subscribe 2005-11-14
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 2008-07-01
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 2012-06-27
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 2015-07-27
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 2007-11-21
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 2012-05-10
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 2005-01-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2005-11-01
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 2007-08-24
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-02-04
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 2016-10-06
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2008-10-14

Supplementary Protection Certificates for Lilly Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0933372 13/2008 Austria ⤷  Try a Trial PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
3141251 301099 Netherlands ⤷  Try a Trial PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
2957286 LUC00094 Luxembourg ⤷  Try a Trial PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
1280520 300722 Netherlands ⤷  Try a Trial PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
2782584 2021C/558 Belgium ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.